Roche announced its fourth China deal since August, teaming up with Chinese biotech Defand on targeted protein-degrader development. The reported deal value is just under $1 billion if milestones are achieved, positioning Defand as a partner in Roche’s ongoing push into protein degradation modalities. The transaction underlines how larger pharma are consolidating next-generation platforms through collaborations with smaller, regionally rooted technology developers—often before programs enter more expensive clinical phases. For biotech firms, this remains a key path to capital and scale: partnering with platforms that can be integrated into broader clinical portfolios.